Literature DB >> 3297707

Bacterial meningitis: is there a "best" antimicrobial therapy?

H F Eichenwald.   

Abstract

The introduction of several cephalosporins into pediatric practice has provided the physician with a number of choices in the treatment of neonatal and childhood meningitis. Adequate studies are available to indicate that these new drugs are as effective as traditional treatments in terms of survival and major neurologic sequelae but it is not known whether the results are worse or better as far as the incidence of more subtle neurologic changes is concerned. The advantages of the cephalosporins in treatment of childhood meningitis are that they permit single drug therapy, the risks of drug toxicity are reduced, and the problems of penicillin-tolerant pneumococci and ampicillin/chloramphenicol-resistant H. influenzae are avoided. When used in the treatment of neonatal disease, the cephalosporins have the advantage of lower toxicity than the aminoglycosides, generally making blood drug level determinations unnecessary, and are effective against strains of bacteria that have become resistant to the latter drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297707     DOI: 10.1007/BF00716463

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  Comparison of ceftriaxone with standard therapy for bacterial meningitis.

Authors:  R W Steele; R W Bradsher
Journal:  J Pediatr       Date:  1983-07       Impact factor: 4.406

2.  Antibiotic therapy of bacterial meningitis: lessons we've learned.

Authors:  M A Sande
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

3.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

4.  Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation.

Authors:  G H McCracken; N Threlkeld; S Mize; C J Baker; S L Kaplan; I Faingezicht; W E Feldman; U Schaad
Journal:  JAMA       Date:  1984-09-21       Impact factor: 56.272

5.  Cefuroxime versus ampicillin plus chloramphenicol in childhood bacterial meningitis: a multicenter randomized controlled trial.

Authors:  W A Marks; H R Stutman; M I Marks; J S Abramson; E M Ayoub; S A Chartrand; F E Cox; W A Geffen; C J Harrison; D Harrison
Journal:  J Pediatr       Date:  1986-07       Impact factor: 4.406

6.  Treatment of bacterial meningitis with ceftazidime.

Authors:  D Hatch; G D Overturf; A Kovacs; D Forthal; C Leong
Journal:  Pediatr Infect Dis       Date:  1986 Jul-Aug

7.  Ceftazidime vs. standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations.

Authors:  W J Rodriguez; J R Puig; W N Khan; J Feris; B G Gold; C Sturla
Journal:  Pediatr Infect Dis       Date:  1986 Jul-Aug

8.  Prospective comparative trial of moxalactam versus ampicillin or chloramphenicol for treatment of Haemophilus influenzae type b meningitis in children.

Authors:  S L Kaplan; E O Mason; S K Mason; F I Catlin; R T Lee; M Murphy; R D Feigin
Journal:  J Pediatr       Date:  1984-03       Impact factor: 4.406

9.  Acute myocardial effects of chloramphenicol in newborn pigs: a possible insight into the gray baby syndrome.

Authors:  J C Werner; V Whitman; H G Schuler; R R Fripp; A M Rannels; C J Kasales; K F LaNoue
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

10.  Once daily ceftriaxone for central nervous system infections and other serious pediatric infections.

Authors:  R Yogev; S T Shulman; E G Chadwick; A T Davis; W Glogowski
Journal:  Pediatr Infect Dis       Date:  1986 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.